Focuses on developing gene therapies to treat ocular and rare diseases, aiming to provide long-lasting therapeutic benefits.
Adverum Biotechnologies, Inc. is a clinical-stage company specializing in gene therapy, focusing on developing innovative treatments for ocular and rare diseases. At the forefront of its pipeline is ADVM-022, a promising gene therapy administered via a single intravitreal injection. This candidate targets chronic retinal conditions such as wet age-related macular degeneration and diabetic macular edema, aiming to provide long-lasting therapeutic benefits.
In addition to its lead product, Adverum Biotechnologies collaborates extensively through license and collaboration agreements with prestigious institutions and organizations including the University of California, Cornell University, GenSight, Lexeo, and Virovek. These partnerships bolster the company's research and development capabilities, enabling it to accelerate the advancement of its gene therapy candidates and broaden its therapeutic potential.
Established in 2006 and headquartered in Redwood City, California, Adverum Biotechnologies (formerly known as Avalanche Biotechnologies, Inc.) continues to push the boundaries of gene therapy innovation. With a strong commitment to addressing unmet medical needs in ocular and rare diseases, the company remains dedicated to leveraging cutting-edge science to improve the lives of patients worldwide.